#United States #Rosemont #Atopic Dermatitis #American Academy of Dermatology #Pediatric Eczema

New Guidelines for Pediatric Atopic Dermatitis

The American Academy of Dermatology (AAD) has made history by releasing the first-ever guidelines dedicated to the prevention and management of atopic dermatitis, commonly known as eczema, specifically in pediatric patients. This significant milestone highlights the unique considerations necessary for treating children under the age of 18, acknowledging that their condition may not mirror that of adults both in presentation and impact.

Currently affecting up to 25% of children globally, eczema is the most prevalent skin condition in the pediatric population. Characterized by symptoms such as itchy skin, dry patches, rashes, and rough bumps, it can considerably diminish the quality of life for affected children and their families.

Recognizing the Need for Specialized Guidelines
Dr. Murad Alam, President of the AAD and a board-certified dermatologist, emphasizes the need for tailored guidelines because eczema in children can differ significantly from adult cases. "Eczema is extremely common in children, and its manifestations are not always aligned with how it presents in adults. Hence, guidelines specifically focused on pediatrics are crucial for optimal care," remarked Alam.

Focus on Prevention
With a collective aim of enhancing preventive approaches, the guidelines reveal insights into managing eczema effectively. Notably, while the search for preventive solutions continues, the guidelines indicate that dietary interventions and environmental tactics such as switching diets or avoiding exposure to dust mites do not possess sufficient evidence to prevent eczema.

The guidelines do establish that the exclusive use of moisturizers is conditionally recommended for children aged 6 months to 3 years, as consistent hydration can aid in lessening the occurrence of eczema.

Empirical Evidence on Treatment
Eczema management has witnessed a surge in available treatments. The newly released guidelines suggest 26 evidence-based recommendations that span topical therapies, phototherapy, and systemic treatments aimed at alleviating symptoms and effectively managing the condition.

Among the robust recommendations are the following:

• - Regular Use of Moisturizers: Essential to diminish the severity of dry and itchy skin.
• - Topical Calcineurin Inhibitors: Such as pimecrolimus and tacrolimus, are suggested for managing flare-ups and as maintenance therapy during periods of remission.
• - Topical Corticosteroids: Recommended as a cost-effective first-line treatment.
• - Phosphodiesterase-4 Inhibitors: Such as crisaborole, which help reduce itchiness.
• - Monoclonal Antibodies: For patients with moderate to severe eczema, treatments like dupilumab have been shown to significantly decrease the severity of symptoms.

On the other hand, the guidelines strongly advise against the use of systemic corticosteroids except in acute, severe flare-ups, promoting their reserved use as short-term interventions.

Empowering Families and Caregivers
The overarching goal of these guidelines is to empower caregivers, patients, and the medical community. Dr. Dawn Davis, co-chair of the AAD's Atopic Dermatitis Guideline Workgroup, stated, "We aim to provide education and clarity so that children receive the best possible care for eczema. Proactive and timely intervention can drastically improve their quality of life and mitigate symptoms."

Dr. Alam adds, "Tailored treatment plans can make a notable difference in children's eczema cases. Starting treatment early can prevent worsening conditions." It is encouraged for families to collaborate with board-certified dermatologists for expert guidance on eczema management.

For Further Information
To learn more about finding a board-certified dermatologist, visit the AAD's website at aad.org/findaderm. The AAD, headquartered in Rosemont, Illinois, has served as a leading force in dermatologic practices and patient care since its inception in 1938.